Precipio, Inc.

NasdaqCM PRPO

Precipio, Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2024

Precipio, Inc. EBIT Margin is NA for the Trailing 12 Months (TTM) ending September 30, 2024. EBIT ratio is the ratio of EBIT to revenue, measuring a company's operating profitability without considering non-operating income or expenses.

Precipio, Inc. EBIT Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -130.65%.

Key data

Date	EBIT Margin	EPS (Basic)	EPS (Diluted)	Shares (Basic, Weighted)

NasdaqCM: PRPO

Precipio, Inc.

CEO	Mr. Ilan Danieli
IPO Date	June 30, 2017
Location	United States
Headquarters	4 Science Park
Employees	51
Sector	Healthcare
Industries Biotechnology

Description

Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.

Key trends

Past 5 years